Member Info for JamYesterday

As I delve further into Creo, I am fascinated by the back story and future outsized growth potential.

Clearly, this share is not for widows and orphans. I estimate that some £120mn of equity has been raised since 2019 at prices varying from 180p down to 20p. And yet the current MC of the company is £70mn, far less than the total capital invested to build the technology and associated infrastructure.

It means the market is assigning a negative value to the company's future potential, or at the very least, giving new investors the entire R&D, the FDA clearances and the global robotic partnerships, for free.

Why, and what does this mean?

One way of looking at it is that early investors paying 180p were paying up for the invention risk. New investors today are paying for "Execution risk".

What would a large, well-funded medtech company, like Medtronic, say, spend to recreate Creo's CROMA platform, Speedboat and Kamaptive IP from scratch today? Far more than £70mn, I expect, and maybe 5-7 years of R&D. So Creo is selling well below its Replacement value.

On the negative side, there must be a negative "AIM" discount. And a funding fear, that the £10mn junior funding commitment cannot be refinanced or repaid at maturity in November.

So there is a considerable "show me" element to the current valuation, as a pre-revenue medtech business, at least at scale even if starting up and growing rapidly.

I am inclined to the positive side of this fascinating market opportunity. The tech is proven, the sales are ramping up, and the November NICE decision will be (fingers crossed) the "Value Unlock" that corrects this somewhat irrational market pricing.

Do we know for sure if Seascape has entered a bid for either the Teratai or Cempaka DROs?

100x more potent than Dox?

Scary. So much depends on the next few months.

This commercial grade industrial diamonds opportunity is a game changer for BRES when it comes to obtaining a funding and offtake deal(s).

It is very bullish, to anyone who delves deeper into the implications of this rns.

Drbiotech,

You make some valid points, and I thank you for that.

I'm still learning to distinguish between genuine posters with original thoughts, however non-consensual, and AI-driven ones, that come across as all -knowing, reasoned commentaries. They pop up all over the place these days. For example, as a Gold and Silver bug, using YouTube increasingly, I and many other experienced investors were taken in by a certain "Asian_Guy" , who seemed very knowledgeable and posted stuff that was about 80% right, but then added spurious sensationalist stuff that fitted his/her agenda but was subsequently shown to be simply made up.

I was initially taken in by Equitable, as a reasonable pov. And this guy may have 1.5mn shares in Creo. I have no idea if this is true. But as I delve more deeply into Creo, I am naturally inclined to try and see all sides of the investment case, and that means wondering if the NICE timeline might slip from November. And also wondering if Creo has built in a margin of safety for Trusts not taking up the ESD knife product within a short time frame due to individual Trust's bureaucracy, budgets or Specialists' resistance for whatever reason. If asking these questions in all sincerity in a public forum is deemed to be a negativity, then that reflects more on the responder than the questioner, in my opinion. Not my problem. I just look for knowledgeable posters willing to spend a few minutes of their time to broaden my knowledge base about Creo, and in so doing, help to spread the word to a wider audience, as I admit I have not come across Creo up until now. My sole biotech investment is Avacta.

Sorry for the long reply. I am interested and willing to read up on the tech, and Creo's place in this rapidly expanding market segment.

And then there is the issue of management, which I have read about from certain posters, given the tortuous road travelled over the past few years in the stockmarket. For another day, perhaps....

Taken from the BRES bb where Equality is getting under genuine posters' skins:

Jam and fellow readers

There is a real possibility that Equality works the night shift in a side alley Indonesian boiler room sweat shop that has no windows. The supervisor and the boiler room team gets paid via a Chinese army post just outside of Shanghai. The rate of payment is per script using AI software and they get extra if we respond to it. The Chinese are really upset if the West establishes its independent supply chains and they get especially peeved if the global new supplier is in Africa. It is all part of an FUD initiative to disrupt financing of new companies and hence why it is done at this time. Of course we can exploit them by responding with positive information that brings in new investors. It is really important to know these type of operations go on in Asia and target companies like Blencowe.

All the best and of course what I write is just my own opinion of course as I assume all our readers have a brain to do their own research and to check veracity.

"Disclaimer: These are personal thoughts & opinions based on publicly available info. Not financial advice. Always do your own DD and consult a professional."

That's the whole point, Equality.

These are NOT your personal thoughts but answers you get by putting a few keystrokes into your preferred AI engine.

You haven't once expressed any personal thoughts or ideas.

What it does is how adroit Equitable is at using AI tools online.

Just go to his preferred Creo bb and you see exactly the same MO, but in reverse. He can't think for himself.

Surely, a positive decision by NICE in November 2026, if there are no delays due to the Committee asking for more review data, doesn't immediately solve CREO's tight cash flow drain situation. Individual Trusts would then be required to offer CREO's robotic tech but the take up won't be immediate and won't be universal. I see a positive decision as a share spike opportunity for CREO to push through a much needed further equity raise, at lesser dilution than would be required now, say.

Why don't you wait and find out, like the rest of us patient PI shareholders?

If the DFC if involved in the P1/2 funding arrangement, it will take longer as we are feeling with a bureaucracy, let's face it. How often do they meet?

What extra assurances do they need?

Do they have to get a deal signed off with this be Critical Minerals body? Etc etc

When does Save get taken private? And at what price?

I swear I'm never going to invest in any company with more than 10% warrants outstanding in relation to issued shares, ever again .

I appreciate the discussion going on here, as a newbie to MKA. Thank you.

Short sighted, thicko reply.

All the chatter here of late has been around our involvement in the US market, so if EXIM passes HyProMag by, the implication is, bad news.

But surely, if the technology is leading edge and strategic, other Western markets will be served as production ramps up, starting with Germany this year.

What am I missing?

Just checking in here, and looking at the 1 year chart. Gosh, that whole move up from 3p to 5p, recently, looks very bullish, until you realise that it was most probably all "arranged" to get this last placing away.

Looking as precarious as ever, now. But the dream remains, for the inner circle (a dwindling bunch).

Russell1, if you are a holder and a believer in the transformational nature of the Pre|cision platform for cancer treatment in the future, rather than fretting over your current in loss position, why don't you add on weakness on a regular basis? None of us knows when the low will be finally in, but take advantage of this current uncertainty about financing/third party endorsement,/clinical trial updates etc with a high degree of confidence that Avacta under current management will deliver.

Anyone else notice the large number of block trades a the end of day? Becoming a daily occurrence.

Dibs, fyi, I've been here for several years now. It's my second largest position, a couple million Shares. don't bleat about it, but I don't have all my eggs in this particular basket, ordering to have a concentrated mini portfolio of gold and silver bullion and miners as well.

I'm just commenting here to pass the time until the big funding news comes along. No hidden agenda.